Anaesthesia and critical care considerations in nerve agent warfare trauma casualties

Resuscitation

Volumn 47, Issue 2, 2000, Pages 113-123

  Weinbroum, Avi A ^a,b   Rudick, Valery ^b   Paret, Gideon ^c   Kluger, Yoram ^b   Abraham, Ron Ben ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Anesthesia; Critical care; Nerve agent; Pyridostigmine; Toxic trauma casualties

Indexed keywords

ALCURONIUM; ATROPINE; BENZODIAZEPINE DERIVATIVE; CHEMICAL WARFARE AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ETOMIDATE; FENTANYL; INHALATION ANESTHETIC AGENT; KETAMINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; MORPHINE; MUSCLE RELAXANT AGENT; NEUROMUSCULAR BLOCKING AGENT; NEUROTOXIN; OPIATE; ORGANOPHOSPHORUS COMPOUND; OXIME; PETHIDINE; PROPOFOL; PYRIDOSTIGMINE; REMIFENTANIL; SARIN; SCOPOLAMINE; SOMAN; SUXAMETHONIUM; TABUN; THIOPENTAL; UNINDEXED DRUG;

ANESTHESIA; ANESTHESIA INDUCTION; ARMY; ARTIFICIAL VENTILATION; BRONCHOSPASM; CARDIOTOXICITY; CHEMICAL WARFARE; CHILDHOOD DISEASE; CONVULSION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DYSPNEA; HEMODYNAMIC MONITORING; HUMAN; INTENSIVE CARE; INTOXICATION; INTRACRANIAL HYPERTENSION; MULTIPLE TRAUMA; MUSCLE WEAKNESS; NEUROTOXICITY; POSTOPERATIVE CARE; PREMEDICATION; PRIORITY JOURNAL; REGIONAL ANESTHESIA; RESPIRATION DEPRESSION; RESPIRATORY CARE; REVIEW;

EID: 0034306912     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9572(00)00216-1     Document Type: Article

References (82)

1. US Army Medical Research Institute of Chemical Defense. Medical Management of Chemical Casualties Handbook, 2nd edn., 1995, pp. 1-10.
2. Karsenty E., Shemer J., Alshech I., et al. Medical aspects of the Iraqi missile attacks on Israel. Isr. J. Med. Sci. 27:(11/12):1991;603-607.
3. Shemer J., Danon Y.L. Eighty years of the threat and use of chemical warfare: the medical-organizational challenge. Isr. J. Med. Sci. 27:(11/12):1991;608-612.
4. Shemer J., Heller O., Danon Y.L. Civilian-military health services contingency program for a mass casualty situation and wartime in Israel. Isr. J. Med. Sci. 27:(11/12):1991;613-615.
5. Shapira Y., Bar Y., Berkenstadt H., Atsmon J., Danon Y.L. Outline for hospital organization for a chemical warfare attack. Isr. J. Med. Sci. 27:(11/12):1991;616-622.
6. Berkenstadt H., Marganit B., Atsmon J. Combined chemical and conventional injuriespathophysiological, diagnostic and therapeutic effects. Isr. J. Med. Sci. 27:(11/12):1991;623-626.
7. Dirnhuber P., French M.C., Green D.M., Leadbeater L., Stratton J.A. The protection of primates against soman poisoning by pretreatment with pyridostigmine. J. Pharm. Pharmacol. 31:(5):1979;295-299.
8. Von Bredow J.D., Adams N.L., Groff W.A., Vick J.A. Effectiveness of oral pyridostigmine and cholinolytic-oxime therapy against soman intoxication in nonhuman primates. Fund. Appl. Toxicol. 17:(4):1991;761-770.
9. Tsao T.C., Juang Y.C., Lan R.S., Shieh W.B., Lee C.H. Respiratory failure of acute organophospate and carbamate poisoning. Chest. 98:(8):1990;631-636.
10. Namba T., Nolte C.T., Jackrel J., Grob D. Poisoning due to OP insecticides. Acute and chronic manifestations. Am. J. Med. 50:(4):1971;475-492.
11. Milby T.H. Prevention and management of organophosphate poisoning. J. Am. Med. Assoc. 216:(13):1971;2131-2133.
12. Sharabi Y., Danon Y.L., Berkenstadt H., et al. Survey of symptoms following intake of pyridostigmine during the Persian Gulf War. Isr. J. Med. Sci. 27:(11/12):1991;656-658.
13. Kluwe WM, Chinn JC, Feder P. Efficacy of pyridostigmine pretreatment against acute soman intoxication in a primate model. Proc. of the 6th Medical Chemical Defense Bioscience Review, August 1987, pp. 227-234.
14. 14C-labeled pyridostigmine in myasthenia gravis. Neurology. 20:(7):1970;634-641.
15. Breyer-Pfaf U., Maier U., Brinkman A.M., Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin. Pharmacol. Ther. 37:(5):1985;495-501.
16. McNall P.G., Wolfson B., Tuazon J.G., Siker E.S. Use of pyridostigmine for the reversal of neuromuscular junction blockade. Anesth. Analg. 48:(6):1969;1026-1032.
17. Keeler J.R. Interactions between nerve agent pretreatment and drugs commonly used in combat anaesthesia. Mil. Med. 155:(11):1990;527-533.
18. Goldfrank L., Flomenbaum N., Lewin N., Weisman R., Howland M.A., Kaul B. Anticholinergic poisoning. J. Toxicol. Clin. Toxicol. 19:(1):1982;17-25.
19. Louhevaara V., Tuomi T., Korhonen O., Jaakkola J. Cardiorespiratory effects of protective devices during exercise in well trained men. Eur. J. Appl. Physiol. 52:(3):1984;340-345.
20. Arad M., Epstein Y., Krasner E., Danon Y.L., Atsmon J. Principles of respiratory protection. Isr. J. Med. Sci. 27:(11/12):1991;636-642.
21. Quinby G.E. Further therapeutic experience with pralidoximes in organic phosphorus poisoning. J. Am. Med. Assoc. 187:1964;202-206.
22. Namba T., Hiraki K. PAM (pyridine-2-aldoxime methiodide) therapy for alkylphosphate poisoning. J. Am. Med. Assoc. 166:1958;1834-1839.
23. Gordon J.J., Leadbeater L., Maidment M.P. The protection of animals against organophosphate poisoning by pretreatment with a carbamate. Toxicol. Appl. Pharmacol. 43:(1):1978;207-216.
24. Keeler J.R., Hurst C.G., Dunn M.A. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. J. Am. Med. Assoc. 266:(5):1991;693-695.
25. Worek F., Szinicz L. Atropine and oxime treatment in lethal soman poisoning of anaesthetized guinea-pigs: Hlö 7 dimethanesulfide versus HI 6 dichloride. Pharmacol. Toxicol. 72:(1):1993;13-21.
26. Borland R.G., Brennan D.H., Nicholson A.N., Smith P.A. Studies on the possible central and peripheral effects in man of a cholinesterase inhibitor (pyridostigmine). Hum. Toxicol. 4:(3):1985;293-300.
27. Caldwell R.W., Lowensohn H.S., Chryssanthis M.A., Nash C.B. Interactions of pyridostigmine with cardiopulmonary system and their relationship to plasma cholinesterase activity. Fund. Appl. Toxicol. 12:(3):1989;432-441.
28. Eyer P., Hagedorn I., Klimmek R., et al. Hlö 7 dimethanesulfonate, a potent bispiridinium-dioxime against anticholinesterases. Arch. Toxicol. 66:1992;603-621.
29. Lundy P.M., Tremblay K.P. Ganglion blocking properties of some bispyridinium soman antagonists. Eur. J. Pharmacol. 60:(1):1979;53-74.
30. Worek F., Szinicz L. Investigation of acute cardiovascular and respiratory toxicity of Hlö 7 dimethanesulfonate and HI 6 dichloride in anesthetized guinea-pigs. Pharmacol. Toxicol. 73:(2):1993;91-95.
31. Worek F., Kleine A., Szinicz L. Effect of pyridostigmine pretreatment on cardiorespiratory function in tabun poisoning. Hum. Exp. Toxicol. 14:(8):1995;634-642.
32. Morita H., Yanagisawa N., Nakajima T., et al. Sarin poisoning in Matsumoto, Japan. Lancet. 346:(8970):1995;290-293.
33. Singer A.W., Jaax N.K., Graham J.S., McLeod C.G. Cardiomyopathy in soman and sarin intoxicated rats. Toxicol. Lett. 36:(3):1987;243-249.
34. Coupland R.M. Epidemiological approach to surgical management of the casualties of war. Br. Med. J. 308:(6945):1994;1693-1697.
35. Coupland R.M., Parker P.J., Gray R.C. Triage of war wounded: The experience of the International Committee of the Red Cross. Injury. 23:(8):1992;507-510.
36. Volans A.P. Sarin: guidelines on the management of victims of a nerve gas attack. J. Accid. Emerg. Med. 13:(3):1996;202-206.
37. Solberg Y., Nachtomi-Shick O., Sehmer Y., Alcalay M. Terror in Japan: mass-intoxication with the nerve agent sarin. Harefuah. 135:(7/8):1998;268-271.
38. Nozaki H., Hori S., Shinozawa Y., et al. Relationship between pupil size and acetylcholinesterase activity in patients exposed to sarin vapor. Int. Care Med. 23:1997;1005-1007.
39. Okudera H., Morita H., Iwashita T., et al. Unexpected nerve gas exposure in the city of Matsumoto: report of rescue activity in the first Sarin gas terrorism. Am. J. Emerg. Med. 15:1997;527-528.
40. Nozaki H., Hori S., Shinozawa Y., et al. Secondary exposure of medical staff to Sarin vapor in the emergency room. Int. Care Med. 21:(12):1995;1032-1035.
41. Kato T., Hamanaka T. Ocular signs and symptoms caused by exposure to sarin gas. Am. J. Ophthalmol. 121:(2):1996;209-210.
42. Advanced Trauma Life Support Instructor Manual. Chicago: American College of Surgeons, 1993.
43. Baker DJ, Rustick JM. Anaesthesia for casualties of chemical warfare agents. In: Anaesthesia and perioperative care of the combat casualty. Office of the Surgeon General, United States Army Medical Department Center, 1995; Part IV: p. 850.
44. Saadeh A.M., Farsakh N.A., Ali M.K. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart. 77:(5):1997;461-464.
45. Chuang F.R., Jang S.W., Lin J.L., Chern M.S., Chen J.B., Hsu K.T. QTc prolongation indicates a poor prognosis in patients with OP poisoning. Am. J. Emerg. Med. 14:(5):1996;451-453.
46. Kato T., Yoshimoto N., Sawano M., Hamabe Y. Coronary vasospasm in a patient suffering from sarin poisoning. Am. J. Emerg. Med. 18:(1):2000;113-114.
47. Benzenoff H.E., McCgee J., Knight V. The hypertensive response to soman and its relation to brain acetylcholinesterase inhibition. Acta Pharmacol. Toxicol. 55:(4):1984;270-277.
48. Wood M. Cholinergic and parasympathomimetic drugs. Cholinesterases and anticholinesterases. Wood M., Wood A.J.J., Drugs and Anaesthesia. 1985;111-140 Williams & Wilkins, Baltimore, MD.
49. Abel V.M., Kohlmeyer K. On the cholinergic-toxic psychosyndrome of prostigmine-treated myasthenics. Dtsch. Med. Wochenschr. 91:(15):1966;699-703.
50. Shale D.J., Lane D.J., Davis C.J. Airflow limitation in myasthenia gravis. The effect of acetylcholine esterase inhibitor therapy on airflow limitation. Am. Rev. Resp. Dis. 128:(4):1983;618-621.
51. Ringqvist I., Ringqvist T. Changes in respiratory mechanics in myasthenia gravis with therapy. Acta Med. Scand. 190:(6):1971;509-518.
52. Ram Z., Molcho M., Danon Y.L., et al. The effect of pyridostigmine on respiratory function in healthy and asthmatic volunteers. Isr. J. Med. Sci. 27:(11/12):1991;664-668.
53. ingston H.G.G., Hirshman C.A. Perioperative management of the patient with asthma. Anesth. Analg. 63:(9):1984;844-855.
54. Carter B.J., Cammermeyer M. Emergency of real casualties during simulated chemical warfare training. Mil. Med. 150:(12):1988;657-665.
55. Frankle W.S., Pool-Wilson P.A. Effects of thiopental on tension development, action potential, and exchange of calcium and potassium in rabbit ventricular myocardium. J. Cardiovasc. Pharmacol. 3:(3):1981;554-558.
56. Pederson L., Benumof J. Incidence and magnitude of hypoxaemia with ketamine in a rural African hospital. Anaesthesia. 48:(1):1993;67-69.
57. Corssen G., Gutierrez G., Reves J.G., Huber F.C. Ketamine in the anesthetic management of asthmatic patients. Anesth. Analg. 51:(4):1972;588-599.
58. Criado A., Maseda J., Navarro E., Escarpa A., Avello F. Induction of anaesthesia with etomidate: hemodynamic study of 36 patients. Br. J. Anaesth. 52:(8):1980;803-806.
59. Wagner R.L., White P.F., Kan P.B., Rosenthal M.H., Feldman M. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. New Engl. J. Med. 310:(22):1984;1415-1421.
60. Rendig S.V., Amsterdam E.A., Henderson G.L., Mason D.T. Comparative cardiac contractile actions of six narcotic analgesics: morphine, meperidine, pentazocine, fentanyl, methadone and L-alpha-acetylmetadol (LAAM). J. Pharmacol. Exp. Ther. 215:(1):1980;259-265.
61. Weinbroum A.A., Halpern P., Rudick V., Sorkine P., Freedman M., Geller E. Midazolam versus propofol for long-term sedation in the ICU: a randomized prospective comparison. Intensive Care Med. 23:(12):1997;1258-1264.
62. Conti G., Dell'Utri D., Vilardi V., et al. Propofol induces bronchodilation in mechanically ventilated chronic obstructive pulmonary disease (COPD) patients. Acta Anaesthesiol. Scand. 37:1993;105-109.
63. Pizov R., Brown R.H., Weiss Y.S., et al. Wheezing during induction of general anaesthesia in patients with and without asthma. A randomized, blinded trial. Anesthesiology. 82:(5):1995;1111-1116.
64. Grob D., Harvey J.C. Effects in man of the anticholinesterase compound sarin. J. Clin. Invest. 37:1958;350-368.
65. Kobayashi O., Ohta Y., Kosaka F. Interaction of sevoflurane, isoflurane, enflurane and halothane with non-depolarizing muscle relaxants and their prejunctional effects at the neuromuscular junction. Acta Med. Okayama. 44:(4):1990;209-215.
66. Moss J., Rosow C.E. Histamine release by narcotics and muscle relaxants in humans. Anesthesiology. 59:(4):1983;330-339.
67. Egan T.D., Lemmens H.J., Fiset P., et al. The pharmacokinetics of the new short-acting opioid remifentanyl (GI87084B) in healthy adult male volunteers. Anesthesiology. 79:(5):1993;881-892.
68. Sunew K.Y., Hicks R.G. Effects of neostigmine and pyridostigmine on duration of succinylcholine action and pseudocholinesterase activity. Anesthesiology. 49:(3):1978;188-191.
69. Kopman A.F., Strachovsky G.S., Lichtenstein L. Prolonged response to succinylcholine following physostigmine. Anesthesiology. 49:(2):1978;142-143.
70. Puhringer F.K., Khuen-Brady K.S., Koller J., Mitterschiffthaler G. Evaluation of the endotracheal intubating conditions of rocuronium (ORG9426) and succinylcholine in outpatient surgery. Anesth. Analg. 75:(1):1992;37-40.
71. Wachtel R.E. Comparison of anticholinesterases and their effects on acetylcholine-activated ion channels. Anesthesiology. 72:(3):1990;426-427.
72. Turner G.A., Williams J.D., Baker D.J. Effects of pretreatment with pyridostigmine on subsequent activity of alcuronium in non-anesthetized subjects. Br. J. Anaesth. 66:(3):1990;365-369.
73. Sopher M.G., Sears D.H., Walts L.F. Neuromuscular monitoring comparing the flexor hallucis brevis and adductor pollicis muscles. Anesthesiology. 69:(1):1988;129-131.
74. DuToit P.W., Muller F.O., Van Tonder W.M., Ungerer M.J. Experience with the intensive care management of OP insecticide poisoning. S. Afr. Med. 60:(6):1981;227-229.
75. DeSilva H.J., Sanmuganathan P.S., Senanayake N. Isolated bilateral recurrent laryngeal nerve paralysis: a delayed complication of organophosphorous poisoning. Hum. Exp. Toxicol. 13:(3):1994;171-173.
76. Senanayake N., Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. New Engl. J. Med. 316:(13):1987;761-763.
77. American Heart Association, 1994. Textbook of Pediatric Advanced Trauma Life Support.
78. Berkendtadt H., Arad M., Nachtomi O., Atsmon J. The effect of chemical protective ensemble on intravenous line insertion by emergency medical technicians. Mil. Med. 164:(10):1999;737-739.
79. Zwiener R.J., Ginsburg C.M. Organophosphate and carbamate poisoning in infants and children. Pediatrics. 81:(5):1988;121-126.
80. Mortensen M.L. Management of acute childhood poisoning by selected insecticides and herbicides. Pediatr. Clin. North Am. 33:(2):1986;431-445.
81. Lifshitz M., Shahak E., Sofer S. Carbamate and organophosphate poisoning in young children. Pediatr. Emerg. Care. 15:(2):1999;102-103.
82. The American Heart Association. Textbook of Pediatric Advanced Life Support. American Academy of Pediatrics, 1994;6:7-9.